- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Brenda Schmidt Discusses Educating People on Their Type 2 Diabetes Risk
There is a lot of energy around educating consumers about their risk for type 2 diabetes, explained Brenda Schmidt, CEO of Solera Health.
There is a lot of energy around educating consumers about their risk for type 2 diabetes, explained Brenda Schmidt, CEO of Solera Health.
Transcript
What is the partnership Solera Health has with the American Diabetes Association to help people with prediabetes find a Diabetes Prevention Program (DPP) provider?
Solera’s really excited about our partnership with the American Diabetes Association, and what we recognized is that there was a lot of energy around educating consumers around their risk for type 2 diabetes and there was a program available to them to reduce their risk and improve their health. But, what we also noticed was that there wasn’t an efficient way for people to identify where a high-quality, local community DPP provider was, and whether they were covered by their insurance.
So, the partnership with the American Diabetes Association allows those people who are identified as high-risk for type 2 diabetes through the American Diabetes Association’s screener to be sent over to Solera for us to actually find a program for them that best meets their unique needs and preferences, verify their eligibility, and enroll them in a program so they can get started on improving their health.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
